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A B S T R A C T
Dyslipidaemia is a significant cardiovascular risk factor. Green tea catechins are known to have
cholesterol-lowering effects.We investigated the beneficial effects of “Benifuuki,” containing
O-methylated catechin, on cardiovascular risk factors, specifically low-density lipoprotein (LDL)
cholesterol levels.One-hundred fifty-five participantswhomet the inclusion criteria were divided
into 3 groups: “Benifuuki,” “Yabukita,” or barley infusion drinkers.We evaluated the changes
in parameters after 12 weeks. Serum LDL cholesterol levels in the “Benifuuki”-consuming par-
ticipants were significantly lower than those in barley infusion-consuming participants without
a green tea habit. Furthermore, the lectin-like oxidized low-density lipoprotein receptor-1 con-
taining apolipoprotein B (LAB) levels in “Benifuuki” drinkers were significantly lower than those
in the barley infusion group and the “Benifuuki” baseline LAB level. In participants without
a green tea habit, “Benifuuki” significantly reduced the serum LDL cholesterol level and the
LAB levels compared to those observed after barley infusion consumption.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the
CC BY license (http://creativecommons.org/licenses/by/4.0/).
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1. Introduction
Recent lifestyles have caused a worldwide increase in
obesity, hypertension, hyperlipidaemia, and cardiovascular
disease (Braitman, Adlin, & Stanton, 1985; Ford, Giles, & Dietz,
2002; Kannel, Dawber, Kagan, Revotskie, & Stokes, 1961).
Hyperlipidaemia is the most significant risk factor for cardio-
vascular disease, and it is well known that lowering serum low-
density lipoprotein (LDL) cholesterol levels helps prevent
cardiovascular disease (Pedersen et al, 1994).
Green tea is a popular beverage in Japan, and some studies
have shown that increased consumption of green tea can reduce
cardiovascular events (Kuriyama et al., 2006). Green tea cat-
echin, one of the polyphenols present in green tea, plays an
important role in the mechanism underlying this reduction in
the risk of cardiovascular events. Catechin prevents lipase ac-
tivity and lipid micellization in the process of digestion, and
decreases serum cholesterol and triglyceride levels (Ikeda et al.,
1992, 2005; Muramatsu, Fukuyo, & Hara, 1986; Sone et al., 2011;
Wu et al., 2012). Green tea catechins consist mainly of (−)-
epicatechin (EC), (−)-epigallocatechin (EGC), (−)-epigallocatechin-
3-O-gallate (EGCG), and (−)-epicatechin-3-O-gallate (ECG). Of
these four components, EGCG decreases the serum choles-
terol level the most (Koo & Noh, 2007). Besides green tea, barley
infusion (Hordeum vulgare) is widely consumed in Japan.
However, unlike green tea, such as “Yabukita (Camellia sinensis
var. Yabukita)” that contains high levels of EGCG, barley infu-
sion does not contain any catechin. The composition of
catechins in green tea varies depending on the source of the
tea leaves, cultivation conditions, and processing. The green
tea “Benifuuki (Camellia sinensis var. Benifuuki)” contains not
only EGCG but also (−)-epigallocatechin-3-O-(3-O-methyl)-
gallate (EGCG″3Me) in abundance. The latter is absent in
“Yabukita,” which is consumed the most in Japan.
EGCG″3Me is absorbed within the digestive tract more ef-
ficiently than EGCG and has a high retention in the blood
(Maeda-Yamamoto, Ema, & Shibuichi, 2007). Hence, EGCG″3Me
is expected to have higher physiological activity. In addition,
its inhibitory effect on histamine release and its potent anti-
allergic activity have been reported (Maeda-Yamamoto et al.,
2009). Furthermore,methylated catechins have anti-obesity, anti-
tumour, and anti-inflammatory effects (Inagaki et al., 2009),
which also explain the interest in “Benifuuki” as a health-
improving beverage. However, it is not yet clear whether
“Benifuuki” has a beneficial effect on lipid metabolism, espe-
cially on the LDL cholesterol level. Therefore, in the present
study, we investigated this potential effect of “Benifuuki” and
compared the results to those obtained with “Yabukita” and
barley infusion.
2. Materials and methods
2.1. Participants
By local advertisement and cooperation with other hospitals,
10160 healthy volunteers were enrolled in the study. Before en-
rolment, the participants underwent thorough screening,
including verification of their medical history, physical exami-
nation, and clinical laboratory tests (including blood chemistry)
(Fig. 1). Only healthy participants who had no current illnesses
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Fig. 1 – Schematic representation of the study protocol. (1) Anthropometric parameter measures included height, body
weight, waist circumference, and body fat ratio. (2) The systolic blood pressure, diastolic blood pressure, and heart rate were
measured. (3) The following parameters were measured in blood sample 1: triglycerides, total cholesterol, low-density
lipoprotein cholesterol, high-density lipoprotein cholesterol, haemoglobin A1c, glucose, immunoreactive insulin, γ-glutamyl
transpeptidase, aspartate aminotransferase, alanine aminotransferase, iron, white blood cell count, red blood cell count,
haemoglobin, haematocrit, and platelet count. (4) The following parameters were measured in blood sample 2: ferritin,
high-sensitive C-reactive protein, malondialdehyde-modified low-density lipoprotein, soluble lectin-like oxidized LDL
receptor-1, lectin-like oxidized LDL receptor-1 ligand containing apolipoprotein B, LOX-index, MCP-1, TNF-a, pentosidine,
and adiponectin. (5) The following parameters were measured in urine sample 1: qualitative assessment of glucose,
protein, urobilinogen, ketone bodies, and blood. (6) The following parameters were measured in urine sample 2: urinary
8-OH-dG. (7) In the subject interviews, a physician evaluated the physical condition and presence of symptoms of adverse
effects due to catechin ingestion. (8) The subjects recorded the intake of the test beverage and the daily symptoms.
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with high LDL cholesterol levels were enrolled. Individuals
within an age range of 20 to 80 years and who met the fol-
lowing inclusion criteria were included: a serum LDL cholesterol
level over 3.10mmol/L and bodymass index (BMI) over 25 kg/m2.
The exclusion criteria included current treatment for arrhyth-
mia, hepatic damage, chronic kidney disease, cerebrovascular
disease, rheumatism, diabetes mellitus, lipid disorder, and/or
anaemia; a history of severe allergy to specific foods and drugs
or a history of heart failure or cardiac infarction; pregnancy
or intention to become pregnant; lactation; and other conditions
judged by the doctor to be unsuitable for inclusion (e.g., use
of supplements affecting lipid parameters [so-called dietary
supplements]). One hundred and sixty-nine participants (64men
and 105 women), aged between 24 and 72 years (mean age:
52.6 ± 10.7 years, median: 51 years), were recruited from late
October 2013 to March 2014. The complete date range for
patient recruitment and follow-up was from 27 October 2013
to 31 May 2014.
The participants were residents of communities in Osaka,
Kyoto, and Hyogo Prefecture in Japan. The baseline sampling
was performed from November 2013 to March 2014.The follow-
up period was 12 weeks.The study was started after the number
of participants enrolled had reached the required number as
planned beforehand.
2.2. Setting
The study was conducted according to the principles of the
“Declaration of Helsinki.”All participants in the study gave their
informed consent. The study was a randomized, double-
blind, placebo-controlled trial and was approved by the Ethics
Committees of Osaka Medical College (No. 1285) (date of ap-
proval: from 3 September 2013 to 31 March 2016) and Osaka
Medical College Health Science Clinic (No. 2011-CR-10) (date
of approval: 29 June 2013). The trial was registered at the Uni-
versity Hospital Medical Information Network Clinical Trials
Registry (UMIN-CTR, No. UMIN000011901).The authors confirm
that all on-going and related trials for this drug/intervention
are registered.
2.3. Interventions, randomization, and blinding
“Benifuuki” green tea was used as the active test tea, and
“Yabukita” green tea or barley infusion as the placebo tea. All
three types of teas were manufactured by Asahi Soft Drinks,
Co., Ltd. (Tokyo, Japan). Barley infusion is not obtained from
Camellia, but it is made from the extract of the plant, like green
tea. We used barley infusion, which does not contain cat-
echins, as one of the control beverages in the study. The tea
was served as an extract powder. The extracted tea powder
(100 mg) was added to 25 mL of distilled water, centrifuged at
1200 g for 5 min at 4 °C, and the supernatant was diluted five-
fold with distilled water. Twenty microlitres of the sample,
filtered through a membrane filter (DISMIC-13HP, PTFE; pore
size = 0.45 µm;Advantec, Osaka, Japan), was injected into a high-
performance liquid chromatography (HPLC) apparatus. HPLC
was performed with a Shimadzu LC-10A pump coupled with
a UV−vis detector (SPD-M10Avp; Shimadzu Corp., Kyoto, Japan)
using a reverse-phase Wakopak Navi C18-5 column (4.6 mm
i.d. × 150 mm; granule diameter, 5 µm;Wako Pure Chemical In-
dustries, Ltd., Osaka, Japan) withWakopak Navi C18-5 (4.6 mm
i.d. × 10 mm; granule diameter, 5 µm;Wako Pure Chemical In-
dustries, Ltd., Osaka, Japan) as a guard column and eluted with
an eluent (as described below) at a flow rate of 1 mL/min at
40 °C. Catechin levels were measured at 272 nm. HPLC analy-
sis was performed using a linear gradient system with mobile
phase A (DW/MeCN/H3PO4, 400:10:1) and mobile phase B
(MeOH/mobile phase A, 1:2). Linear gradient elution was per-
formed as follows: 100% mobile phase A for 2 min; 20% mobile
phase A for 27 min; maintain 20% mobile phase A for 10 min;
and return to 100% mobile phase A for 7 min. Quantification
was carried out using the external standard method. Quanti-
fication of catechins and caffeine was performed after data
acquisition. Each 9 g of tea extract powder contained cat-
echins and O-methylated EGCG in the following amounts,
respectively: barley infusion extract powder, 0.0 mg and 0.0 mg;
“Yabukita” green tea extract powder, 603 mg and 0.0 mg; and
“Benifuuki” green tea extract powder, 607.5 mg and 49.5 mg.
Each aluminium pack contained 3 g powder, which was for one-
time use. The 9 g (3 g × 3) sample of the test tea was the daily
dose. The participants were instructed to consume 3 g of test
tea extract powder three times a day at mealtimes for 12 weeks
by dissolving the powder in 200 mL of water (a daily total of
9 g tea extract powder and 600 mL of water). The catechin and
caffeine contents of the test beverages are presented in Table 1.
The participants were prohibited from consuming any tea other
than the test or placebo tea during the study period; however,
they were allowed to consume any non-tea beverages.
A computer-generated randomization sequence allocated
participants in a 1:1:1 ratio into the barley infusion, “Yabukita”
green tea, or “Benifuuki” green tea groups by the permuted block
Table 1 – The catechins and caffeine content of the test
beverages per day.
Component “Benifuuki”
(mg)
“Yabukita”
(mg)
Barley
infusion
(mg)
O-methylated EGCG
(EGCG″3Me + GCG″3Me)
49.5 0 0
(−)-Epigallocatechin-3-O-
(3-O-methyl)-gallate
(EGCG″3Me)
42.3 0 0
Gallocatechin-3-O-(3-O-
methyl)-gallate
(GCG″3Me)
7.2 0 0
Eight types of catechins 558 603 0
Gallocatechin (GC) 39.6 52.2 0
(−)-Epigallocatechin (EGC) 147.6 132.3 0
Catechin (C) 11.7 27 0
(−)-Epicatechin (EC) 54 40.5 0
(−)-Epigallocatechin-3-O-
gallate (EGCG)
210.6 243 0
Gallocatechin-3-O-gallate
(GCG)
34.2 57.6 0
(−)-Epicatechin-3-O-
gallate (ECG)
55.8 44.1 0
Catechin-3-O-gallate (CG) 4.5 6.3 0
Total catechins 607.5 603 0
Caffeine 125.1 129.6 0
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method (block size was kept constant). Each tea was wrapped
individually in an aluminium package labelled with an allo-
cation number, which was created by a third party not directly
involved in the study to ensure that the study investigators and
participants were blinded to the type of tea provided.
2.4. Primary and secondary endpoints
The original primary endpoints were serum total cholesterol
and serum LDL cholesterol levels.The secondary endpoints were
(1) body weight, body fat ratio [measured using the body com-
position analyser (bioelectrical impedance analysis [BIA];
InnerScan® 50V, Tanita Co., Tokyo, Japan)], waist, and blood
pressure [measured twice after a 3-minute rest using a
sphygmomanometer (ES-P2000BR®,Terumo Co.,Tokyo, Japan)];
(2) triglyceride levels, lectin-like oxidized low-density lipopro-
tein receptor-1 (LOX-1) index (obtained by multiplying the LAB
[LOX-1 ligand containing ApoB] by the sLOX-1 [soluble LOX-1]
level); (3) fasting plasma glucose, HbA1c (described by both
the NGSP HbA1c [as %] and SI, IFCC-recommended units [as
mmol/mol)), and insulin levels; (4) high sensitivity C-reactive
protein (CRP), catechin-sensing molecule level; (5) each tea’s
in vivo antioxidant action, and pentosidine and urinary 8-OH-
dG level; (6) levels of the cytokines monocyte chemoattractant
protein-1 (MCP-1), tumour necrosis factor (TNF) α, high sen-
sitivity CRP, and adiponectin; (7) aspartate aminotransferase
(AST), alanine aminotransferase (ALT), and γ glutamyl
transpeptidase (ɣGTP) level; (8) serum iron and ferritin level;
(9) adiponectin level; (10) urinalysis; and (11) diet survey. The
participants were requested to fill in questionnaires on their
health, lifestyle, and food intake. They were also asked to fill
in a questionnaire on the strength of the green tea that they
usually drank and the frequency of green tea consumption. Bio-
chemical tests were performed in the laboratory of the LSI
Medience Co., Tokyo, Japan. We employed the Food Fre-
quency Questionnaire as used in the Osaki National Health
Insurance cohort (Kuriyama et al., 2006) to evaluate the intake
of tea catechins aside from those present in the test bever-
ages.We evaluated each endpoint after analysis of all the data.
We evaluated the participants’ daily catechin intake via a diet
survey before the start of the study, and we performed a sub-
group analysis according to the presence or absence of a habit
of daily tea drinking.
2.5. Participant instructions
Overeating and over-drinking were avoided as much as pos-
sible during the study period from one week before the start
of the test beverage ingestion. Participants were instructed not
to change their everyday lifestyle, including eating habits,
smoking, and exercise, as much as possible. All participants
were instructed not to consume unregulated drugs and supple-
ments, and other types of tea, which could have a potential
influence on the body fat or serum lipid level measured during
the examination period from one week before the start of test
beverage ingestion. The participants were told that they were
not permitted to have a meal but could drink water after 22:00
on the night preceding examination. They were further in-
structed to keep a record of their adherence to the test beverage
and their physical condition (daily living record).
2.6. Sample size determination
The target number of cases was determined by referring to pre-
vious human intervention trials. LDL-cholesterol and oxidized
LDL cholesterol levels were significantly reduced by daily cat-
echin ingestion as shown in human intervention trials of 22
to 240 participants (group size was 22 to 120 participants)
(Hirano-Ohmori et al., 2005; Inami et al., 2007; Nagao, Hase, &
Tokimitsu, 2007). It is also known that green tea catechins
reduce the serum cholesterol levels of hyperlipidaemic pa-
tients by amean value of about 0.129mmol/L (5mg/dL). Previous
studies on the effect of “Benifuuki” on lipid metabolism did
not exist. “Benifuuki,” which is similar to “Yabukita” but with
a greater level of O-methylated catechins, is expected to be as
or more potent and could reduce mean serum cholesterol levels
by approximately the same degree as other green teas. This
observed reduction is regarded as a clinically relevant im-
provement. Moreover, clinical knowledge suggests that the
standard deviation of the reduction in serum cholesterol levels
with both types of tea is 0.103 mmol/L (4 mg/dL) (Kim et al.,
2011). Sample size calculations were based on the primary out-
comes of serum total cholesterol and LDL cholesterol levels.
The sample size calculations assumed that the statistical analy-
sis would be based on a comparison between the barley
infusion, “Yabukita,” and “Benifuuki” groups (assuming 13%
failure rate in each group). The significance level was set at
α = 0.05. If there is truly no difference in the change in serum
total cholesterol and LDL cholesterol levels between the barley
infusion, “Yabukita,” and “Benifuuki” groups, then 35 partici-
pants are required for 80% confidence.The calculated number
of 150 participants in the present human intervention trial was
based on these previous studies.
2.7. Statistical methods
The significance of the differences in the mean values and in
the proportions of the parameters between the barley infu-
sion, “Yabukita” green tea, and “Benifuuki” green tea groups
was assessed using the Kruskal–Wallis test, Dunnmultiple com-
parison test, and the chi-square test as appropriate (JMP® v11.2.1;
SAS Institute Inc., Cary, NC, USA). The significance of the dif-
ferences in the mean values and in the proportions of the
parameters between pre- and post-intervention was as-
sessed by paired t-test as appropriate. Parameters that showed
a significant difference in the Kruskal–Wallis test were analysed
by the Dunn’s multiple comparison test.The significance level
was set at p < 0.05.The intention-to-treat analysis was also per-
formed. Subgroup analysis was performed between the two
participant groups with and without a habit of daily tea drink-
ing. All participants were prohibited from consuming any tea
other than the test tea, irrespective of their habit of daily tea
drinking, during the study period, and such prohibition might
have affected the outcomes.
3. Results
3.1. Participant flow and follow-up
A total of 169 participants were allocated to the “Benifuuki”
group (n = 56), “Yabukita” group (n = 60), and barley infusion
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group (n = 53). The study lasted 12 weeks. Of these partici-
pants, 20 were excluded from the study for the following
reasons: (1) At baseline, 14 participants (5 in the “Benifuuki,”
5 in the “Yabukita,” and 4 in the barley infusion group) did not
meet the inclusion criteria. (2) During the study period, 1 par-
ticipant in the “Benifuuki” group did not tolerate the bitterness
of the test tea, and 1 other consumed tea other than the test
tea. (3) Lastly, 4 participants in the “Yabukita” group com-
menced drug treatment for hypertension or dyslipidaemia, had
psychological reasons to leave the study, or experienced a sub-
stantial change in their living environment. Consequently, 149
participants (53 men and 96 women; 49 [16 men and 33 women]
in the “Benifuuki” group, 51 [20 men and 31 women] in the
“Yabukita” group, and 49 [17 men and 32 women] in the barley
infusion group) completed the study (Fig. 2). These partici-
pants all met the inclusion and exclusion criteria, and none
of them was taking any drugs for dyslipidaemia.
3.2. Baseline data and outcome
At baseline, among several of the parameters evaluated, only
the ɣGTP and LAB levels were significantly different between
the three groups (Table 2) (Supplementary Table S1). None
of the subjects took methylated catechin before the start of the
trial, and the amount of total catechin intake showed no sig-
nificant difference among the three groups in pre-intervention
by the Kruskal–Wallis test (Benifuuki 280.0 ± 423.1 mg/day,
Yabukita 451.9 ± 769.9 mg/day, barley infusion 294.1 ± 578.8 mg/
day; p = 0.7260). The intake rate of the test tea was 96.0 ± 5.4%,
94.9 ± 6.5%, and 96.1 ± 5.8% in the “Benifuuki,” “Yabukita,” and
barley infusion groups, respectively, and there was no signifi-
cant difference between the three groups.
Among the three groups, only the “Benifuuki” group showed
a significant decrease in the serum cholesterol and LDL cho-
lesterol levels at the end of the study compared with those at
baseline (Table 2). At the end of the 12-week study, the primary
endpoints, serum total cholesterol levels, and LDL choles-
terol levels did not differ significantly between the three groups
(Figs 3 and 4). Among the secondary endpoints, the LAB level
significantly decreased in the “Benifuuki” group at the end of
the study compared with that at baseline (Fig. 5). In addition,
the LAB level significantly decreased at the end of the study
in the “Benifuuki” group compared with that in the barley in-
fusion group (“Benifuuki” vs. barley infusion = −1.0 ± 2.6 mg cs/L
vs. 0.2 ± 3.3 mg cs/L, p = 0.0405) (Table 3) (Fig. 5). No signifi-
cant difference in the urinalysis, participant interview, and daily
living record was observed between the three groups (data not
shown).
No significant difference in the daily calorie intake at the
start and the end of the study was observed in the “Benifuuki”
group, as evaluated using the Food Frequency Questionnaire.
In contrast, the “Yabukita” and barley infusion groups showed
a significant decrease in the daily calorie intake at the end of
the study compared with that at baseline.
Assessed for eligibility (n = 10160)
Excluded (n = 9991)
¨ Not meeting inclusion criteria (n = 9318)
¨ Declined to participate (n = 687)
Analysed (n = 49, 16/33)
¨ Excluded from analysis (n = 0)
Continued intervention (n = 51, 19/32) 
¨ Lost to follow-up (n = 0)
Allocated to intervention (n = 56,21/35)
¨ Received allocated intervention (n = 56,24/35)
¨ Did not receive allocated intervention (n = 0)
Continued intervention (n = 49, 17/32)
¨ Lost to follow-up (n = 0)
Allocated to intervention (n = 53, 19/34)
¨ Received allocated intervention (n = 53 , 19/34)
¨ Did not receive allocated intervention (n = 0)
Analysed (n = 49, 17/32)
¨ Excluded from analysis (n = 0)
Allocation
Analysis
Follow-Up
Randomized (n = 169)
Enrollment
Continued intervention (n = 55, 22/33)
¨ Lost to follow-up (n = 0)
Allocated to intervention (n = 60, 24/36)
¨ Received allocated intervention (n = 60 , 24/36)
¨ Did not receive allocated intervention (n = 0)
Analysed (n = 51, 20/31)
¨ Excluded from analysis (n = 0)
“Benifuuki” “Yabukita” Barley infusion
Initial laboratory test
¨ Discontinued intervention (n = 5)
BMI <25 (n=0), LDL <120 (n = 3)
HbA1c >8.0% (n = 2)
Initial laboratory test
¨ Discontinued intervention (n = 5)
BMI <25 (n=0), LDL <120 (n = 4)
HbA1c >8.0% (n = 1)
Initial laboratory test
¨ Discontinued intervention (n = 4)
BMI <25 (n=2), LDL<120 (n = 2)
HbA1c >8.0% (n = 0)
Discontinued intervention (n = 2)
test beverage was bitter (n = 1),
personal reason (n = 1)
Discontinued intervention (n = 4)
medical treatment (n = 2),
mental disorder (n = 1),
personal reason (n = 1)
Discontinued intervention (n = 0)
Fig. 2 – Flowchart of the study (n = all number, men/women).
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Table 2 – Baseline characteristics and changes in the anthropometric values and biochemical parameters after drinking
“Benifuuki,” “Yabukita,” or barley infusion for 12 weeks. ALL, all participants; YES, participants with a habit of daily tea
drinking; NO, participants without a habit of daily tea drinking.
Interventions Week 0 Week 12 Δ value at
week 12a
Paired
t test
p-value of multiple
comparison testc
Drinking tea habit
p-valueb ALL YES NO
Baseline characteristics
Sex (men/women) “Benifuuki” 16/33
“Yabukita” 20/31 0.7811 0.6569 0.7649
Barley infusion 17/32
Age “Benifuuki” 51.3 ± 10.4
“Yabukita” 52.4 ± 10.4 0.5375 0.4297 0.9558
Barley infusion 53 ± 10.6
Diet survey
Total daily intake
(kcal/day)
“Benifuuki” 1979 ± 173.2 1962.6 ± 200.3 −16.4 ± 112.6 0.3127
“Yabukita” 2081.5 ± 294.0 2027.0 ± 283.9 −54.5 ± 127.1 0.0035** 0.4200 0.4626 0.3466
Barley infusion 2060.6 ± 271.3 2005.3 ± 258.3 −55.4 ± 169.5 0.0267*
Protein (g/day) “Benifuuki” 80.3 ± 7.3 79.5 ± 7.8 −0.8 ± 4.5 0.2249
“Yabukita” 81.8 ± 9.1 80.6 ± 8.5 −1.2 ± 5.8 0.1407 0.5153 0.8263 0.3445
Barley infusion 82.7 ± 11.0 79.4 ± 8.6 −3.4 ± 8.4 0.0072**
Fat (g/day) “Benifuuki” 61.1 ± 5.4 60.3 ± 4.9 −0.8 ± 3.2 0.0970
“Yabukita” 61.8 ± 5.3 61.5 ± 5.5 −0.3 ± 3.8 0.5711 0.9208 0.9756 0.6951
Barley infusion 62.4 ± 6.3 60.8 ± 5.2 −1.7 ± 5.5 0.0415*
Carbohydrate (g/day) “Benifuuki” 260.4 ± 22.9 257.3 ± 32 −3.1 ± 28.5 0.4467
“Yabukita” 285.8 ± 56.4 269.9 ± 47.4 −15.9 ± 29.1 0.0003*** 0.1576 0.3263 0.1715
Barley infusion 277.3 ± 43.0 266.6 ± 36.5 −10.7 ± 31.2 0.0209*
Anthropometric values
Body weight (kg) “Benifuuki” 71.8 ± 10.0 71.5 ± 9.7 −0.3 ± 1.6 0.1610
“Yabukita” 72.9 ± 12.4 72.7 ± 12.2 −0.2 ± 1.4 0.3152 0.0646 0.4374 0.0807
Barley infusion 72.5 ± 11.4 72.9 ± 11.6 0.4 ± 1.5 0.0415*
Body mass index
(kg/m2)
“Benifuuki” 27.6 ± 2.3 27.5 ± 2.3 −0.1 ± 0.6 0.2078
“Yabukita” 28.3 ± 3.2 28.2 ± 3.2 −0.1 ± 0.5 0.4237 0.0824 0.5207 0.0866
Barley infusion 28.0 ± 2.7 28.1 ± 2.8 0.2 ± 0.6 0.0511
Waist circumference
(cm)
“Benifuuki” 94.0 ± 6.7 94.3 ± 6.9 0.3 ± 3.2 0.5263
“Yabukita” 95.0 ± 8.3 95.2 ± 8.3 0.3 ± 2.7 0.4942 0.7754 0.9331 0.3396
Barley infusion 95.9 ± 6.4 96.6 ± 5.7 0.7 ± 4 0.1878
SBP (mm Hg) “Benifuuki” 127.7 ± 14.2 127 ± 14.7 −1.6 ± 9.7 0.5696
“Yabukita” 129.1 ± 17.1 125.5 ± 17.5 −2.5 ± 13.0 0.0244* 0.1625 0.5093 0.0799
Barley infusion 131.0 ± 20.5 125.2 ± 22.7 −6.5 ± 16.3 0.0087**
DBP (mm Hg) “Benifuuki” 83.8 ± 11.7 82.8 ± 11.6 −1.6 ± 8.0 0.5696
“Yabukita” 84.0 ± 11.3 80.6 ± 11.9 −3 ± 9.6 0.0244* 0.2616 0.8214 0.1199
Barley infusion 86.5 ± 10.7 81.7 ± 11.3 −4.5 ± 8.8 0.0087***
Pulse (bpm) “Benifuuki” 72.5 ± 9.2 73.8 ± 9.7 1.7 ± 9.0 0.2466
“Yabukita” 72.9 ± 8.9 74 ± 9.6 0.9 ± 9.8 0.3680 0.2078 0.5584 0.2442
Barley infusion 73.6 ± 9.2 72.4 ± 9.2 −1.8 ± 7.3 0.2345
Body fat ratio (%) “Benifuuki” 33.8 ± 7.3 29.2 ± 8.4 −4.6 ± 6.8 <.0001****
“Yabukita” 33.9 ± 7.6 31.0 ± 10.5 −2.9 ± 6.3 0.0020** 0.2457 0.1594 0.5475
Barley infusion 34.6 ± 7.8 31.0 ± 9.4 −3.9 ± 5.6 <.0001****
Lipid parameters
Total cholesterol
(mmol/L)
“Benifuuki” 6.39 ± 0.73 6.24 ± 0.68 −0.16 ± 0.55 0.0496*
“Yabukita” 6.27 ± 0.74 6.16 ± 0.79 −0.12 ± 0.69 0.2397 0.4583 0.7885 0.021*
Barley infusion 6.20 ± 0.70 6.26 ± 0.78 0.06 ± 0.69 0.5610
Triglyceride (mmol/L) “Benifuuki” 1.73 ± 0.94 1.69 ± 0.96 −0.04 ± 0.94 0.7693
“Yabukita” 1.45 ± 0.79 1.45 ± 0.96 0.00 ± 0.82 0.9801 0.6559 0.9690 0.4051
Barley infusion 1.48 ± 0.59 1.58 ± 0.72 0.10 ± 0.54 0.2086
HDL cholesterol
(mmol/L)
“Benifuuki” 1.57 ± 0.40 1.55 ± 0.37 −0.02 ± 0.17 0.4459
“Yabukita” 1.55 ± 0.39 1.55 ± 0.38 0.00 ± 0.18 0.8906 0.8433 0.6447 0.9756
Barley infusion 1.57 ± 0.35 1.56 ± 0.37 −0.02 ± 0.18 0.5581
LDL cholesterol
(Friedewald) (mmol/L)
“Benifuuki” 4.05 ± 0.55 3.92 ± 0.62 −0.13 ± 0.45 0.0450*
“Yabukita” 4.06 ± 0.74 3.96 ± 0.75 −0.10 ± 0.62 0.2443 0.5044 0.6581 0.0162*
Barley infusion 3.95 ± 0.55 3.97 ± 0.63 0.03 ± 0.58 0.7421
(continued on next page)
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Table 2 – (continued)
Interventions Week 0 Week 12 Δ value at
week 12a
Paired
t test
p-value of multiple
comparison testc
Drinking tea habit
p-valueb ALL YES NO
Glycometabolism-associated parameters
HbA1c (mmol/mol) “Benifuuki” 37.9 ± 4.0 38.5 ± 5.1 0.6 ± 2.3 0.0642
“Yabukita” 38.1 ± 6.3 38.4 ± 5.7 0.3 ± 2.4 0.3104 0.9877 0.7727 0.6124
Barley infusion 37.7 ± 3.7 38.5 ± 5.4 0.8 ± 3.2 0.1040
HbA1c (%) “Benifuuki” 5.61 ± 0.37 5.67 ± 0.47 0.06 ± 0.21 0.0642
“Yabukita” 5.64 ± 0.58 5.67 ± 0.52 0.03 ± 0.22 0.3104 0.9877 0.7727 0.6124
Barley infusion 5.60 ± 0.34 5.67 ± 0.49 0.07 ± 0.29 0.1040
Blood glucose
(mmol/L)
“Benifuuki” 4.90 ± 0.57 5.12 ± 0.75 0.22 ± 0.47 0.0026**
“Yabukita” 4.89 ± 0.74 4.92 ± 0.76 0.03 ± 0.35 0.5792 0.2013 0.1489 0.0759
Barley infusion 4.70 ± 0.56 4.97 ± 1.10 0.27 ± 0.88 0.0392*
IRI (µU/mL) “Benifuuki” 6.8 ± 2.9 7.9 ± 3.4 1.0 ± 2.5 0.0058**
“Yabukita” 7.2 ± 3.9 7.6 ± 3.0 0.4 ± 3.1 0.3173 0.8422 0.9350 0.8411
Barley infusion 8.3 ± 4.0 10.5 ± 8.8 2.2 ± 8.3 0.0746
HOMA-IR “Benifuuki” 1.5 ± 0.7 1.8 ± 1.0 0.3 ± 0.7 0.0014**
“Yabukita” 1.6 ± 0.9 1.7 ± 0.9 0.1 ± 0.7 0.2401 0.6741 0.8229 0.6704
Barley infusion 1.8 ± 0.9 2.6 ± 3.3 0.8 ± 3.1 0.0660
LOX index-associated parameters
sLOX-1 (ng/L) “Benifuuki” 464.5 ± 118.7 593.7 ± 199.1 129.2 ± 223.2 0.0002***
“Yabukita” 485.5 ± 122.5 637.3 ± 207.1 152 ± 241.8 <.0001**** 0.8767 0.6655 0.9726
Barley infusion 498.7 ± 158.6 614.5 ± 181.5 115.7 ± 220.8 0.0006***
LAB (mg cs/L) “Benifuuki” 5.05 ± 1.81 4.01 ± 1.68 −1.04 ± 2.60 0.0070**
“Yabukita” 4.61 ± 1.76 4.18 ± 1.97 −0.44 ± 2.53 0.2253 0.0453* 0.0204* 0.6611
Barley infusion 4.23 ± 2.09 4.66 ± 2.19 0.42 ± 3.25 0.3653
LOX index “Benifuuki” 2364.9 ± 1070.2 2426.5 ± 1308.6 61.5 ± 1764.7 0.8080
“Yabukita” 2241.8 ± 976.4 2724.1 ± 1560.3 482.4 ± 1818.3 0.0639 0.1767 0.1337 0.8494
Barley infusion 2154.7 ± 1516.3 2905 ± 1782.7 750.2 ± 2450.2 0.0372*
Cytokines
MCP-1 (pg/mL) “Benifuuki” 107.6 ± 55.6 105.1 ± 44.3 −4.7 ± 50.1 0.5173
“Yabukita” 108.5 ± 39.8 103.2 ± 41.8 −5.3 ± 29.1 0.1979 0.7361 0.7059 0.9549
Barley infusion 106.7 ± 47.1 99.7 ± 35.9 −9.0 ± 39.3 0.1157
TNF-α (pg/mL) “Benifuuki” 0.7 ± 0.3 0.8 ± 0.3 0.1 ± 0.4 0.1108
“Yabukita” 0.8 ± 0.4 1.0 ± 0.5 0.2 ± 0.5 0.0214*** 0.2736 0.1628 0.8964
Barley infusion 1.1 ± 1.5 1.1 ± 0.8 0.1 ± 0.9 0.6703*
Adiponectin (µg/mL) “Benifuuki” 8.5 ± 3.9 9.0 ± 4.2 0.4 ± 1.0 0.0044**
“Yabukita” 9.2 ± 4.5 9.4 ± 4.9 0.2 ± 1.5 0.2859 0.9013 0.8767 0.9876
Barley infusion 9.6 ± 3.9 9.9 ± 4.2 0.3 ± 1.3 0.1359
High sensitivity CRP
(µg/L)
“Benifuuki” 1091.6 ± 1144.3 1114.7 ± 1272.4 23.1 ± 1179.6 0.8917
“Yabukita” 940.6 ± 988.3 1091.2 ± 1316.4 150.6 ± 1371.1 0.4365 0.8894 0.1798 0.1662
Barley infusion 1260.4 ± 1286.4 1334.7 ± 1290.2 74.3 ± 1393.6 0.7107
A biomarker for advanced glycation end products
Pentosidine
(pmol/mL)
“Benifuuki” 106 ± 30.2 106.1 ± 29.4 0.4 ± 33.3 0.9329
“Yabukita” 113 ± 32.8 99.1 ± 29.6 −13.6 ± 36.9 0.0109* 0.0965 0.2723 0.1248
Barley infusion 105 ± 26 100 ± 27.2 −4.6 ± 31.4 0.3107
Complete blood count
Hb (g/L) “Benifuuki” 142.8 ± 14.0 140.6 ± 13.1 −2.2 ± 5.5 0.0080**
“Yabukita” 144.1 ± 13.3 144.1 ± 13.9 0.1 ± 6.1 0.9450 0.2792 0.6995 0.2366
Barley infusion 144.0 ± 13.1 142.8 ± 13.3 −1.2 ± 7.1 0.2574
Hct (/L) “Benifuuki” 0.44 ± 0.04 0.43 ± 0.03 −0.01 ± 0.02 0.0001***
“Yabukita” 0.44 ± 0.03 0.44 ± 0.04 0.00 ± 0.02 0.5983 0.0674 0.2966 0.2541
Barley infusion 0.44 ± 0.03 0.43 ± 0.04 −0.01 ± 0.02 0.0479*
RBC (104/µL) “Benifuuki” 473 ± 44 467 ± 39 −7 ± 18 0.0163*
“Yabukita” 475 ± 36 476 ± 36 2 ± 18 0.4562 0.1451 0.6333 0.0888
Barley infusion 474 ± 37 472 ± 37 −2 ± 19 0.3805
Plt (104/µL) “Benifuuki” 26.9 ± 4.9 26.9 ± 5.4 0 ± 2.8 0.9713
“Yabukita” 26.6 ± 5.1 26 ± 4.8 −0.5 ± 2.2 0.1067 0.6668 0.8954 0.1042
Barley infusion 25.6 ± 3.9 25.7 ± 4.6 0.1 ± 3.3 0.7579
WBC (/µL) “Benifuuki” 5884 ± 1712 5708 ± 1858 −176 ± 1114 0.2775
“Yabukita” 5916 ± 1618 5682 ± 1607 −233 ± 985 0.0968 0.8246 0.2592 0.5704
Barley infusion 5863 ± 1454 5592 ± 1468 −271 ± 1232 0.1294
(continued on next page)
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Fig. 3 – The change in the total cholesterol level from week 0 to week 12 (including sub-group analysis: the presence or
absence of a habit of daily tea drinking). Dunn’s multiple comparison test, mean ± SD. ALL, all participants; YES,
participants with a habit of daily tea drinking; NO, participants without a habit of daily tea drinking. Black bars: “Benifuuki”
green tea group; grey bars: “Yabukita” green tea group; white bars: barley infusion group.
Table 2 – (continued)
Interventions Week 0 Week 12 Δ value at
week 12a
Paired
t test
p-value of multiple
comparison testc
Drinking tea habit
p-valueb ALL YES NO
Liver functions
AST (U/L) “Benifuuki” 24.8 ± 10.9 24.6 ± 9.6 −0.3 ± 6.8 0.7705
“Yabukita” 23.5 ± 7.9 23.1 ± 8.4 −0.4 ± 4.9 0.5300 0.8636 0.9341 0.4724
Barley infusion 23.9 ± 7.6 24.8 ± 9.8 0.9 ± 9.8 0.5435
ALT (U/L) “Benifuuki” 29.3 ± 18.3 29.9 ± 19.9 0.6 ± 13.5 0.7438
“Yabukita” 28.2 ± 20.8 28.2 ± 22.9 0 ± 9.2 0.9879 0.8191 0.3425 0.6364
Barley infusion 29.1 ± 13.4 28.6 ± 15.4 −0.6 ± 8.9 0.6537
γGTP (U/L) “Benifuuki” 53.9 ± 42.4 54.1 ± 44.4 0.1 ± 24.0 0.9716
“Yabukita” 36.5 ± 27.5 36.4 ± 24.4 −0.1 ± 18.1 0.9754 0.1010 0.0893 0.8395
Barley infusion 40.5 ± 34.7 35.5 ± 22.5 −5 ± 17.8 0.0544
Iron metabolism
Fe (µmol/L) “Benifuuki” 20.86 ± 7.94 18.37 ± 6.46 −2.49 ± 9.66 0.0780
“Yabukita” 20.51 ± 7.79 19.85 ± 6.81 −0.66 ± 7.60 0.5376 0.3642 0.9635 0.1557
Barley infusion 20.19 ± 5.74 19.79 ± 6.32 −0.41 ± 7.34 0.6979
Ferritin (ng/mL) “Benifuuki” 134 ± 108 133.7 ± 117.2 0.2 ± 32.8 0.9637
“Yabukita” 155 ± 143 142.1 ± 123.3 −12.8 ± 40.4 0.0282* 0.5034 0.2659 0.9093
Barley infusion 160 ± 138 151.8 ± 140.4 −8.1 ± 56.2 0.3205
All data are mean ± standard deviation except the sex parameter.The ɣGTP and LAB levels were significantly different between the three groups
at baseline. “Benifuuki” group, n = 49; “Yabukita” group, n = 51; barley infusion group, n = 49. The initial values were not significantly different
between the groups except for the LAB values.
HbA1c is described by both the NGSP HbA1c (as %) and SI, IFCC-recommended units (as mmol/mol) in this manuscript.
a The value is the change from Week 0 to Week 12.
b A paired t-test was performed in each group to compare the data at baseline and after 12 weeks intervention (*p < 0.05, **p < 0.01, ***p < 0.001,
****p < 0.0001)
c p-values reflect overall comparison of the groups by Kruskal–Wallis test (p-values of only sex parameter reflect overall comparison of the
groups by Pearson’s chi-square test).
SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; HbA1c, haemoglobin
A1c; IRI, immunoreactive insulin; HOMA-IR, homeostatic model assessment of insulin resistance; sLOX-1, soluble lectin-like oxidized low-
density lipoprotein receptor-1; LAB, ligands containing apolipoprotein B; MCP-1, monocyte chemoattractant protein-1; TNF-α, tumour necrosis
factor α; CRP, C-reactive protein; Hct, haemoglobin count; RBC, red blood cell count; Plt, platelet count; WBC, white blood cell count; AST, as-
partate aminotransferase; ALT, alanine aminotransferase; γ GTP, γ glutamyl transpeptidase.
32 J o u rna l o f Func t i ona l F ood s 2 5 ( 2 0 1 6 ) 2 5 – 3 7
3.3. Ancillary analysis
A subgroup analysis was performed between the two partici-
pant groups with (n = 100) and without (n = 49) a habit of daily
tea drinking. In the groupwithout a habit of daily tea drinking,
the primary endpoints, serum total cholesterol levels, and LDL
cholesterol levels significantly decreased at the end of the study
in the“Benifuuki”groupwhen comparedwith those in the barley
infusion group (total cholesterol, “Benifuuki” vs. barley infu-
sion = −0.40 ± 0.48 mmol/L vs. 0.33 ± 0.72 mmol/L,p = 0.0185; LDL
cholesterol,“Benifuuki”vs. barley infusion = −0.32 ± 0.33 mmol/L
vs. 0.21 ± 0.56 mmol/L, p = 0.0127) (Figs 3 and 4) (Table 3). No
significant change in the triglyceride andHDL cholesterol levels
at the start and the end of the study was observed between
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Fig. 4 – The change in the LDL cholesterol level from week 0 to week 12 (including sub-group analysis: the presence or
absence of a habit of daily tea drinking). Dunn’s multiple comparison test, mean ± SD. ALL, all participants; YES,
participants with a habit of daily tea drinking; NO, participants without a habit of daily tea drinking. Black bars: “Benifuuki”
green tea group; grey bars: “Yabukita” green tea group; white bars: barley infusion group.
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Fig. 5 – The change in LOX-1 ligands containing ApoB (LAB) level from week 0 to week 12 (including the sub-group analysis:
the presence or absence of a habit of daily tea drinking). Dunn’s multiple comparison test, mean ± SD. ALL, all participants;
YES, participants with a habit of daily tea drinking; NO, participants without a habit of daily tea drinking. Black bars:
“Benifuuki” green tea group; grey bars: “Yabukita” green tea group; white bars: barley infusion group.
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the three groups. However, in the participants with a habit of
daily tea drinking, the LAB level significantly decreased in
the “Benifuuki” group compared with that in the barley infu-
sion group.
3.4. Test beverage-associated adverse events
No adverse effects were observed in any of the participants in
the three study groups in terms of glucose metabolism,
including the fasting plasma glucose and the HbA1c level. Simi-
larly, peripheral blood analysis, liver functions, and ferrous
metabolism confirmed the safety of all three test beverages.
4. Discussion
Green tea is a highly consumed beverage in Japan. Increased
consumption has been reported to be associated with de-
creased all-cause mortality and mortality due to cardiovascular
diseases (Kuriyama et al., 2006). Green tea may also affect lipid
metabolism, as shown by several studies revealing its
cholesterol- and triglyceride-lowering effects (Muramatsu et al.,
1986; Wu et al., 2012). Catechins contained in green tea have
been implicated in the underlying mechanism of these effects.
Furthermore, Ikeda et al. (1992) showed that green tea cat-
echins inhibited the intestinal absorption of cholesterol in rats
by suppressing the micellization of cholesterol, and these cat-
echins suppressed postprandial hypertriglyceridaemia by
delaying the lymphatic transport of dietary fat (Ikeda et al.,
2005). It was reported that the EGCG concentration in blood
plasma can be determined after green tea administration
(Nakagawa & Miyazawa, 1997), that EGCG improves choles-
terol metabolism through the up-regulation of the LDL receptor,
and that EGCG reduces extracellular apoB levels (Goto, Saito,
Morikawa, Kanamaru, & Nagaoka, 2012).
The green tea catechins displaying these effects are mainly
EC, EGC, EGCG, and ECG, and EGCG is the most potent. In stark
contrast to barley infusion, both “Benifuuki” and “Yabukita”
contain abundant EGCG. In addition, “Benifuuki” contains
EGCG″3Me, which is not present in “Yabukita.” EGCG″3Me dis-
plays higher intestinal absorption efficiency than any other
catechin (Maeda-Yamamoto et al., 2007). Moreover, it has a
unique anti-allergic effect that is not observed with the other
catechins (Masuda, Maeda-Yamamoto, Usui, & Fujisawa, 2014).
It was reported that compared with the effects observed for
“Yabukita,” “Benifuuki” significantly inhibited the expression
of genes involved in the synthesis of cholesterol and
Table 3 – Changes in the biochemical parameters after drinking “Benifuuki,” “Yabukita,” or barley infusion for 12 weeks
with the p-value < 0.05 by Kruskal–Wallis test. Dunn’s multiple comparison test, mean ± SD. ALL, all participants; YES,
participants with a habit of daily tea drinking; NO, participants without a habit of daily tea drinking.
Interventions Week 0 Week 12 Δ value at week 12 p-valuea p-valueb
ALL
Total cholesterol (mmol/L) “Benifuuki” 6.39 ± 0.73 6.24 ± 0.68 −0.16 ± 0.55 0.0469*
“Yabukita” 6.27 ± 0.74 6.16 ± 0.79 −0.12 ± 0.69 0.2397 1.0000
Barley infusion 6.20 ± 0.70 6.26 ± 0.78 0.06 ± 0.69 0.5610 0.7701
LDL cholesterol (Friedewald) (mmol/L) “Benifuuki” 4.05 ± 0.55 3.92 ± 0.62 −0.13 ± 0.45 0.0450*
“Yabukita” 4.06 ± 0.74 3.96 ± 0.75 −0.10 ± 0.62 0.2443 1.0000
Barley infusion 3.95 ± 0.55 3.97 ± 0.63 0.03 ± 0.58 0.7421 0.7747
LAB (mg cs/L) “Benifuuki” 5.05 ± 1.81 4.01 ± 1.68 −1.04 ± 2.60 0.0070**
“Yabukita” 4.61 ± 1.76 4.18 ± 1.97 −0.44 ± 2.53 0.2253 0.9407
Barley infusion 4.23 ± 2.09 4.66 ± 2.19 0.42 ± 3.25 0.3653 0.0405*
YES
Total cholesterol (mmol/L) “Benifuuki” 6.35 ± 0.71 6.30 ± 0.72 −0.05 ± 0.55 0.5735
“Yabukita” 6.34 ± 0.75 6.21 ± 0.76 −0.13 ± 0.70 0.2901 1.0000
Barley infusion 6.31 ± 0.75 6.23 ± 0.76 −0.08 ± 0.63 0.4542 1.0000
LDL cholesterol (Friedewald) (mmol/L) “Benifuuki” 4.10 ± 0.55 4.05 ± 0.61 −0.05 ± 0.47 0.5540
“Yabukita” 4.15 ± 0.79 4.02 ± 0.77 −0.13 ± 0.59 0.2030 1.0000
Barley infusion 4.02 ± 0.60 3.95 ± 0.64 −0.07 ± 0.58 0.5007 0.8185
LAB (mg cs/L) “Benifuuki” 4.89 ± 1.9 3.97 ± 1.54 −0.91 ± 2.64 0.0524
“Yabukita” 4.53 ± 1.94 4.04 ± 1.79 −0.49 ± 2.63 0.2860 1.0000
Barley infusion 4.11 ± 2.11 5.01 ± 2.15 0.90 ± 3.21 0.1238 0.0200*
NO
Total cholesterol (mmol/L) “Benifuuki” 6.49 ± 0.79 6.09 ± 0.58 −0.40 ± 0.48 0.0068**
“Yabukita” 6.14 ± 0.73 6.05 ± 0.84 −0.09 ± 0.70 0.6097 0.8003
Barley infusion 5.99 ± 0.55 6.32 ± 0.83 0.33 ± 0.72 0.0826 0.0185*
LDL cholesterol (Friedewald) (mmol/L) “Benifuuki” 3.93 ± 0.56 3.61 ± 0.54 −0.32 ± 0.33 0.0021**
“Yabukita” 3.88 ± 0.60 3.84 ± 0.72 −0.04 ± 0.68 0.8056 0.3579
Barley infusion 3.82 ± 0.44 4.03 ± 0.62 0.21 ± 0.56 0.1431 0.0127*
LAB (mg cs/L) “Benifuuki” 5.43 ± 1.57 4.08 ± 2.02 −1.35 ± 2.55 0.0603
“Yabukita” 4.78 ± 1.36 4.45 ± 2.32 −0.33 ± 2.14 0.5807 1.0000
Barley infusion 4.47 ± 2.09 4.01 ± 2.19 −0.46 ± 3.24 0.5625 1.0000
a Paired t test (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).
b Dunn’s multiple comparison test (vs Benifuuki) (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).
Number of participants = “Benifuuki”/”Yabukita”/barley infusion; ALL = 49/51/49, YES = 34/34/32, NO = 15/17/17.
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significantly upregulated the hepatic mRNA expression of
CYP7A1,which converts cholesterol into bile acids (Suzuki et al.,
2013). “Benifuuki” is speculated to exert a stronger cholesterol-
lowering effect than any other tea through the effects of
EGCG″3Me.
The present study has demonstrated that “Benifuuki” sig-
nificantly decreased total cholesterol and LDL cholesterol levels
during a 12-week period when compared with those at base-
line. Unexpectedly, “Yabukita,” which contains abundant
catechins, did not significantly decrease the total cholesterol
and LDL cholesterol levels, an effect similar to that observed
for the non-catechin-containing barley infusion.Although a sig-
nificant decrease in the total cholesterol and LDL cholesterol
levels was found in the “Benifuuki” group, no statistically sig-
nificant difference in these serum levels was found between
the 3 beverage test groups. According to a meta-analysis (Kim
et al., 2011) that examined the effect of green tea on lipid me-
tabolism, green tea lowers total cholesterol and LDL cholesterol
levels. However, the LDL cholesterol-lowering effect of the green
tea depends on the study design, the study period, the amount
of catechin, the population, etc.Two-thirds of the present study
subjects had a habit of drinking green tea, as do many Japa-
nese people. There is a possibility that this had an influence
on the results of the present study, which did not include a
wash-out period. Therefore, we separated the subjects based
on tea habit to evaluate the effect of catechin more clearly. In
the group without a tea habit, green tea, as expected, had a
significant effect on the reduction of total and LDL choles-
terol levels in comparison with the effect of barley infusion.
Several reports describe the relationship between choles-
terol and risk of cardiovascular disease.The Framingham Heart
Study, for example, identified hypercholesterolaemia as a risk
factor for ischaemic heart disease (Kannel et al., 1961). Past
studies have revealed a relationship between the rise in cho-
lesterol levels and an increase in coronary heart disease
mortality (Leren, 1970; Verschuren et al., 1995). Dyslipidaemia,
especially a high LDL cholesterol level, is a significant risk factor
for coronary heart disease, a typical atherosclerotic disease (Liu
& Li, 2015).
Given the above findings, we hypothesize that “Benifuuki”
reduces the risk for cardiovascular disease through its total
cholesterol- and LDL cholesterol-lowering effects, and its effects
on LAB, soluble LOX-1, and the LOX-index, which were used
as parameters for atherosclerosis. Our study showed that com-
pared with barley infusion, “Benifuuki” significantly decreased
LAB levels irrespective of a habit of daily tea drinking. In ad-
dition, “Benifuuki” significantly reduced LAB levels compared
with those at baseline. On the other hand, the sLOX-1 levels
and LOX-index were not significantly different among the 3
groups.
LOX-1 is an endothelial receptor for oxidized LDL, and the
binding of oxidized LDL to LOX-1 promotes endothelial dys-
function; thus, LOX-1 functions as an aggravating factor at every
stage of atherosclerosis upon binding of oxidized LDL
(Sawamura et al., 1997; Yoshimoto et al., 2011). It was re-
ported that LAB was higher in arteriosclerosis mice and was
significantly reduced by anti-oxidation treatment (Kakutani,
Ueda, Naruko, Masaki, & Sawamura, 2001; Oka, Yasuhara,
Suzumura, Tanaka, & Sawamura, 2006). These reports suggest
that LAB accelerates atherosclerosis and that its plasma
concentration may help predict the development of future ath-
erosclerosis. To the best of our knowledge, the present study
is the first to show that “Benifuuki,” which contains EGCG″3Me,
significantly reduces the LAB level, suggesting that EGCG″3Me
reduces the LAB level through a mechanism different from that
of other catechins.
The serum sLOX-1 level, together with the serum LOX-1 level,
is considered to reflect the progression of sclerosis and in-
flammation of the arteries (Sawamura, Wakabayashi, &
Okamura, 2015). In the present study, a significant increase in
the sLOX-1 levels was observed in all 3 groups, but no signifi-
cant difference was observed between the 3 groups.The sLOX-1
levels significantly increased in each group before and after
the intervention; there were no differences between the groups
in this study. It was reported that there is a strong seasonal
effect, with cholesterol levels being higher in winter than in
summer (Robinson, Hinohara, Bevan, & Takahashi, 1993).While
there has been no report of seasonal changes in sLOX-1 levels
to date, it may be a possibility since it is a lipid metabolism-
related parameter. The LOX-index reflects the interaction
between sLOX-1 and LAB and is considered a biomarker for
cardiovascular diseases. However, there was no difference in
the LOX-index between the groups in the present study. Fur-
thermore, Okamura et al. (2013) investigated carotid intima-
media thickness (IMT) and found that in US Caucasians, a
higher LAB level was significantly associated with increased
IMT.
High LAB and LOX-index levels, apart from high LDL cho-
lesterol levels, are suggested to be risk factors for atherosclerosis.
Our present study demonstrated that “Benifuuki” not only sig-
nificantly reduced the LDL cholesterol level but also significantly
decreased that of LAB and of oxidized LDL, suggesting a role
of “Benifuuki” in delaying the ageing process.We believe that
this is due to catechins derived from green tea suppressing the
micellization of cholesterol in the intestinal tract, and EGCG″3Me
inhibiting the synthesis of cholesterol and promoting excre-
tion of cholesterol to bile acid through excellent absorption
efficiency of EGCG″3Me from the intestinal tract. Among the
3 tea extracts, although the difference was not significant,
“Benifuuki” showed the strongest LOX-index-lowering effect,
suggesting that “Benifuuki”might prevent cardiovascular events.
If we had used a larger amount (e.g., two or three times) of tea
catechins in the present study, a more clear effect of tea cat-
echins on lipid metabolism would have likely been obtained.
However, we also recognized that it would not be easy for a
person without a tea drinking habit to take high doses of tea
catechins daily.
A limitation of our study is that polyphenols contained in
chocolate, wine, and certain other foods were not evaluated
in the Food Frequency Questionnaire because only the con-
sumption of polyphenols present in tea and coffee were
restricted.Another limitation of our study is that we could blind
all test beverages in terms of appearance but could not blind
all test beverages in terms of taste. Since patients with heart
disease and cerebrovascular disorders were not included in the
present study, the study results may not be extrapolated to high-
risk group patients with atherosclerotic disease. There might
be a bias because some participants could not continue the
study. Six participants out of one hundred fifty-five partici-
pants were excluded after their initial allocation. Since green
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tea consumption was assessed based on self-administered
questionnaires, some misclassification of the consumption
status could have affected the estimation of the effect of the
respective test beverage. However, this misclassification seems
likely to have been non-differential and would tend to result
in an underestimation of the impact of green tea consump-
tion. In addition, as mentioned previously, a washout period
was not included in the study design.
5. Conclusions
“Benifuuki” significantly decreased serum LAB levels when com-
pared with barley infusion. Furthermore, in the participant
group without a habit of daily green tea consumption,
“Benifuuki” significantly reduced serum total cholesterol and
LDL cholesterol levels when compared with barley infusion.
Thus, consumption of “Benifuuki” green tea may help prevent
cardiovascular diseases by lowering serum LDL cholesterol and
LAB levels.
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